Adam Colborn of AMCP Gives a Legislative, Regulatory Update in the Pharmacy Space and Shares Concern on OOP Medicare Part D Copay Assistance | AMCP Nexus 2023
Adam Colborn, JD, director of Government Relations at AMCP, addressed topics at this year's AMCP Nexus conference in Orlando such as transparency, cost sharing mandates and variables that affect the supply and demand curve for pharmaceuticals within legislation at a federal, but mainly state level. Colborn also touched on the large PBM reform regulation happening currently in New York as it could be a model that other states can follow.
Part one of two
Adam Colborn, JD, director of Government Relations at AMCP, addressed topics at this year's AMCP Nexus in Orlando such as transparency, cost sharing mandates and variables that affect the supply and demand curve for pharmaceuticals within legislation at a federal, but mainly state level.
Colborn also touched on the large PBM reform regulation happening currently in New York as it could be a model that other states can follow.
In an interview with MHE, Colborn shared what AMCP is keeping their eyes on in terms of the IRA. He mentioned his team has shown concern over Medicare drug price negotiation and out-of-pocket "smoothing" or copay assistance for those under Medicare Part D.
Colborn added the OOP "smoothing" is could be a large burden for retail and community pharmacists as they are the patient’s point of contact.
"It raises questions about 'how will a part D plan react if a patient changes their plan or they are unable to pay the rest of their prescription cost under a smoothing arrangement," he said. "It's a good first step but there are a lot of questions that still remain to be answered."
How Prime Therapeutics Tugged on the Reins of the Galloping GLP-1 Spend | AMCP Nexus 2023
October 20th 2023The Minnesota-based pharmacy benefit manager says a program that resulted in patients switching from two incretin therapy prescriptions to one yielded $7,500 in savings per patient and a total of $3.5 million.
Read More
Race, Income Impact Specialty Drug Use of Autoimmune Condition Treatments | AMCP Nexus 2023
October 20th 2023In a platinum award winning poster presented at the AMCP Nexus 2023 conference in Orlando, “Specialty drug use varies by race and wage among employees with employer-sponsored health insurance,” authors expressed that spending on specialty medications for autoimmune conditions has increased in recent years, raising affordability concerns for employers.
Read More
The Oncology Pipeline Is Delivering Exciting New Treatments — and Sticker Shock | AMCP Nexus 2023
October 19th 2023Research continues to develop new therapies for rare cancers and to provide options that allow for fewer toxicities. At the same, however, more new drugs are launching with high price tags.
Read More
The Benefits of ML, AI Use in Managed Care Pharmacy | AMCP Nexus 2023
October 19th 2023Adopting evolving computer system tools like artificial intelligence and machine learning in managed care pharmacies have resulted in efficiency when addressing the challenges they are faced with, according to Jessica Hatton, PharmD, BCACP, associate vice president of Pharmacy at CareSource and Nick Trego, PharmD, senior vice president of Clinical Analytics and Client Services at HealthPlan Data Solutions, Inc.
Read More
Outcomes From Horizon BCBS of New Jersey Oncology Home Infusion Program | AMCP Nexus 2023
October 19th 2023The program yielded savings of $25,000 per patient in its pilot phase but is not expected to produce savings as a routine offering because reimbursement for home infusion was matched to reimbursement at a facility. Horizon executive Timothy O’Shea, Pharm.D., M.S., says cost savings were a “secondary outcome” of the program and noted the high patient satisfaction.
Read More
